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Abstract
Background: Tumor necrosis factor-· (TNF-·) is involved
in the pathogenesis of chronic active hepatitis C. Poly-
morphisms in the promoter region of the TNF-· gene can
alter the TNF-· expression and modify the host immune
response. The present study aimed at the correlation of
the G308A TNF-· polymorphism with the response to
antiviral combination therapy in chronic hepatitis C. Pa-
tients and Methods: 62 patients with HCV and 119
healthy unrelated controls were genotyped for the
G308A TNF-· promoter polymorphism. The patients re-
ceived 3 ! 3 million units of interferon alfa-2a and 1,000–
1,200 mg ribavirin daily according to their body weight.
A response was defined as absence of HCV-RNA and
normalization of S-ALT after 6 months of combination
therapy. Results: With respect to the allele and genotype
frequency, a significant difference was not observed
between controls and patients with chronic hepatitis C.
Furthermore, such a difference was also not observed if
responders and non-responders to antiviral therapy
were compared. Conclusions: The promoter polymor-
phism of the TNF-· gene investigated herein is equally
distributed in healthy individuals and patients with hepa-
titis C and does not seem to predict the response to ther-
apy with interferon alfa-2a and ribavirin.
Copyright © 2003 S. Karger AG, Basel
Introduction
The response to therapy with interferon alfa-2a and
ribavirin in chronic active hepatitis C depends on various
factors such as age, gender, viral genotype, viral load,
duration of infection and presence of liver fibrosis [1].
Cytotoxic effects of multiple cytokines, which confer the
inflammatory process in viral hepatitis, might additional-
ly influence the response to antiviral therapy. Moreover,
different HLA subtypes [2–4] and the chemokine receptor
5 [5, 6] might be of paramount importance for the patho-
physiology of chronic hepatitis C. In addition, cytokines
such as interleukin-10 [7] or the tumor necrosis factor-·
(TNF-·) [8] seem to influence the course of the disease.
Comparable to various other inflammatory conditions,
TNF-· is released in chronic hepatitis C and contributes
to the pathogenesis of the liver injury [8, 9]. In particular,This work contains parts of the doctoral thesis of C. Simperl.
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Table 1. Clinical and laboratory characteristics of the HCV patients
and controls
Characteristic HCV patients
(n = 62)
Controls
(n = 119)
Female/male 28/34 49/70
Age (mean B SD) 42B11 39B12
S-ALT, U/l 74B45 normal
Viral load, !106 U/ml 2.46B0.45 –
Genotypes 1 or 4 37 –
Genotypes 2 or 3 25 –
elevated serum levels of TNF-· mRNA, the respective
receptor or increased intrahepatic TNF-· mRNA expres-
sion were described in viral hepatitis [8–10]. Two G to A
transition polymorphisms, at positions –238 and –308 in
the TNF-· promoter region, influence TNF-· expression
[11, 12] and were associated with the presence of liver cir-
rhosis in chronic hepatitis C [13]. In addition, it was sug-
gested that enhanced intrahepatic mRNA levels of TNF-·
might reflect resistance to interferon [14], because these
levels were significantly higher in non-responders when
compared to responders [15]. The latter finding is com-
patible with intrahepatic TNF-· expression being a host
factor that might predict the outcome of antiviral combi-
nation therapy with interferon alfa-2a and ribavirin [15].
Hence, the present study evaluated the distribution of
the G308A TNF-· promoter polymorphism in controls
and patients with hepatitis C and assessed the response to
antiviral therapy after stratification for this polymor-
phism in patients with chronic active hepatitis C.
Patients and Methods
Patients
The study population comprised 62 patients with chronic active
hepatitis C and 119 healthy unrelated controls. Overall, 80 patients
with chronic hepatitis C had been enrolled in a prospective trial
which evaluated the treatment options in patients with concomitant
psychiatric disorders, previous drug abuse or current methadone sub-
stitution compared with a control group. A detailed description of
the study including the number of drop-outs and side effects of the
medication has already been reported elsewhere [16].
Inclusion criteria were elevated liver enzymes (alanine amino-
transferase, S-ALT 130 U/l) and a positive PCR for HCV-RNA.
DNA was available for genotyping from 62 patients. For the correla-
tion between the TNF-· genotype and the virologic response, only
patients who completed 6 months of therapy (n = 59) were evaluated
in the statistical analysis. The baseline characteristics of the patients
and controls are given in table 1. All patients were treated with inter-
Table 2. Distribution of the –308 TNF-·
promoter genotypes in patients and controls
Genotypes HCV patients Controls
GG 44 (71%) 86 (73%)
GA 16 (26%) 29 (24%)
AA 2 (3%) 4 (3%)
feron alfa-2a (Roferon®, Hoffmann-La Roche, Germany) in a dosage
of 3 ! 3 million units per week combined with ribavirin (Rebetol®,
Essex Pharma, München, Germany) in a dosage of 1,000–1,200 mg
daily according to their body weight. A response to therapy was
defined as normalization of aminotransferases and absence of detect-
able HCV-RNA after 6 months. The sustained virological response
was defined as absence of HCV-RNA 6 months after cessation of
antiviral combination therapy. The study was approved by the local
Ethics Committee and all patients gave written informed consent.
Determination of the G308A TNF-· Promoter Polymorphism
Genomic DNA was prepared from buffy coat layers employing a
commercially available kit (QIAamp DNA Blood Mini Kit, Quiagen,
Hilden, Germany). A fragment of the TNF-· promoter gene contain-
ing the G308A polymorphism was amplified by polymerase chain
reaction (PCR) with a forward primer P1 (5)-AGG CAA TAG GTT
TTG AGG GCC AT-3)) and a reverse primer P2 (5)-TCC TCC CTG
CTC CGA TTC CG-3)) as described elsewhere [17]. The PCR was
performed using HotStarTaq DNA Polymerase (Quiagen) in a ther-
mocycler (Biometra, Göttingen, Germany) applying the following
conditions: 1 cycle at 95°C for 15 min, 35 cycles with a denaturation
at 94 °C for 30 s, annealing at 52°C for 30 s and extension at 72°C
for 30 s with a last polymerization step at 72°C for 10 min. Allele 1
has a guanine (TNF-· 308G), which is substituted by an adenine at
position –308 in the polymorphic allele 2.
Restriction analysis was performed with a NcoI digestion which
allowed the identification of the separate alleles. The PCR products
were analyzed on a 4% NuSieve gel (BioProducts, Rockland, Me.,
USA).
Statistics
All data are given as mean B 1 SEM. Statistical analysis was per-
formed using Fisher’s exact test and Mann-Whitney U test, respec-
tively. The influence of the G308A TNF-· polymorphism on the
response to therapy was evaluated using Fisher’s exact test. Results
were then confirmed calculating multiway frequency tables employ-
ing a log-linear model using BMDP software, version 7.0. p values of
!0.05 were considered significant.
Results
Among patients with hepatitis C the allele –308 A was
less frequent (20/124 = 16%) than the wild-type allele
TNF-· 308G (104/124 = 86%), which was comparable to
the distribution in controls (15 vs. 85%, n.s.). The geno-
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type distribution in patients and controls was nearly iden-
tical (table 2).
59 patients completed 6 months of therapy with inter-
feron alfa-2a and ribavirin. 32 (54%) (15 with HCV geno-
types 1/4, 17 with HCV genotypes 2/3) were responders
and 27 (46%) (21 with HCV genotypes 1/4, six with HCV
genotypes 2/3) were non-responders. Among patients with
genotypes GA or AA, the number of responders (n = 9)
and non-responders (n = 9) was identical (fig. 1a). Among
homozygous carriers of the wild-type allele (GG), 23
patients (56%) were responders and 18 (44%) were non-
responders (p = 0.44) after 6 months of therapy (fig. 1a).
One patient with GA and 4 patients with GG genotype
experienced a relapse 6 months after cessation of antiviral
combination therapy. However, a significant difference
was also not observed if the sustained virological response
was considered (fig. 1b).
Discussion
In hepatitis C the host immune response is of pivotal
importance for the course of the disease. Thus, it appears
possible that polymorphisms of genes which impair the
expression of cytokines might be associated with chronic
hepatitis C. In particular, the distribution of these poly-
morphisms in patients with chronic hepatitis C as com-
pared to healthy controls and the response to therapy in
carriers vs. non-carriers might be of interest. TNF-· is a
pro-inflammatory cytokine which plays a key role in the
host immune response. The gene for TNF-· is situated
within the MHC class III region on chromosome 6p21.3
[18]. A bi-allelic G (TNF1 allele) to A (TNF2 allele) poly-
morphism at position 308 results in elevated TNF-· levels
[19]. Carriers of this allele are prone to autoimmune dis-
orders like systemic lupus erythematosus, insulin-depen-
dent diabetes mellitus, celiac disease, autoimmune hepa-
titis, primary sclerosing cholangitis [20–22] and infec-
tious diseases such as leprosy and tuberculosis [23, 24]. In
addition, the TNF2 allele was associated with a compli-
cated course following liver transplantation [25, 26]. Last-
ly, this polymorphism is essential for the immune re-
sponse in lymphoid malignancies (e.g. non-Hodgkin’s
lymphoma) and aplastic anemia and influences treatment
outcome [27, 28]. The TNF2 allele was also associated
with the progression of neurodegenerative diseases [29].
Based on these observations, the G308A TNF-· promoter
polymorphism might be of relevance for the susceptibili-
ty, the course and the treatment outcome in chronic active
hepatitis C [8–10].
Fig. 1. a Virologic response according to the G308A TNF-· promot-
er polymorphism after 6 months of therapy. Homozygous (AA) and
heterozygous (GA) carriers are classified as TNF-· 308A, homozy-
gous carriers of the wild-type allele as TNF-· 308G. b Sustained viro-
logic response according to the G308A TNF-· promoter polymor-
phism (6 months after cessation of therapy). Homozygous (AA) and
heterozygous (GA) carriers are classified as TNF-· 308A, homozy-
gous carriers of the wild type allele as TNF-· 308G.
However, a correlation between the TNF2 allele and
the presence of chronic hepatitis C or the response to
antiviral therapy was not observed herein, even if sus-
tained response rates were considered. These findings
confirm and extend the results of recently published stud-
ies [30, 31]. On the other hand, further genes, such as
TGF-ß, appear to be associated with resistance to antivi-
ral treatment [32, 33]. Hence, a definite conclusion about
the impact of the host immune response for the course of
hepatitis C cannot be drawn yet.
Nevertheless, the currently available data argue strong-
ly against a correlation between the G308A TNF-· pro-
moter gene polymorphism and the susceptibility to
chronic hepatitis C or the outcome following combination
therapy with interferon alfa-2a and ribavirin.
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